secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021086
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026
--------------------------------------------------------------------------------

- Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.
- Cash and investments: $600.5M as of Dec 31, 2023, expected to fund operations through 2026.
- BLA for axatilimab in chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.
- NDA for revumenib in R/R KMT2Ar acute leukemia submitted under RTOR; PDUFA date expected 1Q24.
- Enrollment in AUGMENT-101 mNPM1 cohort to complete late 1Q/early 2Q; topline data in 4Q24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/0000950170-24-021086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024021086/sndx-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer